--- schema_version: "secwatch.filing_event.v1" accession: "0000914121-23-000003" form_type: "8-K" ticker: "ANGO" cik: "0001275187" company_name: "ANGIODYNAMICS INC" filed_at: "2023-01-05T23:59:59+00:00" generated_at: "2026-06-20T19:21:02.292602+00:00" event_type: "earnings" sentiment: "positive" materiality_score: 0.7 calibrated_materiality_score: 0.7 confidence: "high" source: SEC EDGAR --- # AngioDynamics Q2 FY2023 sales $85.4M (+9.1% YoY); GAAP loss $0.21/sh, adj EPS $0.01; reaffirms guidance ## Summary - Net sales $85.4M, up 9.1% YoY; Med Tech +29.7% to $24.5M, Med Device +2.6% to $60.9M. - GAAP net loss $0.21 per share; adjusted EPS $0.01 vs adjusted loss $0.02 a year ago. - Adjusted EBITDA $7.5M, up from $4.4M in prior-year quarter. - FY2023 guidance reaffirmed: net sales $342-348M, gross margin ~52.5-54.5%, adj EPS $0.01-$0.06. - Cash $29.9M, $50M in debt; Preserve prostate cancer study enrollment passed midpoint. ## SEC filing metadata - accession: 0000914121-23-000003 - form_type: 8-K - ticker: ANGO - cik: 0001275187 - company_name: ANGIODYNAMICS INC - filed_at: 2023-01-05T23:59:59+00:00 - event_type: earnings - sentiment: positive - materiality_score: 0.7 - calibrated_materiality_score: 0.7 - confidence: high - sec_items: 2.02, 7.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/0000914121-23-000003-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/an58427779-8ki.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000914121-23-000003 - JSON: https://secwatch.observer/filing/0000914121-23-000003.json - Plain text: https://secwatch.observer/filing/0000914121-23-000003.txt ## Key facts - Earnings Releases ANGIODYNAMICS INC reported the fiscal second quarter ended November 30, 2022 results: revenue $85.4 million, net income net loss of $8.5 million, EPS loss per share of $0.21. - Period: the fiscal second quarter ended November 30, 2022 - Revenue: $85.4 million - Net income: net loss of $8.5 million - EPS: loss per share of $0.21 - Result: reported results source text: Net sales for the second quarter of fiscal 2023 were $85.4 million, an increase of 9.1% compared to the prior-year quarter. Foreign currency translation did not have a significant impact on the Company ' s net sales in the quarter. Med Tech net sales were $24.5 million, a 29.7% increase from the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform and the NanoKnife irreversible electroporation platform. Growth was driven by Auryon sales during the quarter of $10.1 million, which increased 60.6%, and NanoKnife sales of $5.5 million, which increased 49.5% compared to the second quarter of fiscal 2022. NanoKnife disposable sales were $4.2 million, which increased 45.4% compared to the second quarter of fiscal 2022. Med Device net sales were $60.9 million, an increase of 2.6% compared to the prior-year period. U.S. net sales in the second quarter of fiscal 2023 were $71.6 million, an increase of 9.6% from $65.4 million a year ago evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/0000914121-23-000003-index.htm - Earnings Releases ANGIODYNAMICS INC reported the six months ended November 30, 2022 results: revenue $167.0 million, net income net loss of $21.5 million, EPS loss of $0.55 per share. - Period: the six months ended November 30, 2022 - Revenue: $167.0 million - Net income: net loss of $21.5 million - EPS: loss of $0.55 per share - Result: reported results source text: For the six months ended November 30, 2022: Net sales were $167.0 million, an increase of 7.5%, compared to $155.3 million for the same period a year ago. Med Tech net sales were $47.3 million, a 29.7% increase from the prior year period. Med Device net sales were $119.6 million, an increase of 0.7% from the prior year period. Gross margin increased 30 basis points to 52.3% from 52.0% a year ago. The Company’s net loss was $21.5 million, or a loss of $0.55 per share, compared to a net loss of $15.3 million, or a loss of $0.39 per share, a year ago. Excluding the items shown in the non-GAAP reconciliation table, below, adjusted net loss was $2.1 million, with adjusted loss per share of $0.05, compared to adjusted net loss and adjusted loss per share of $1.7 million, and $0.04, respectively, a year ago. Adjusted EBITDA, excluding the items shown in the reconciliation table below, was $10.4 million, compared to $8.0 million for the same period a year ago. evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/0000914121-23-000003-index.htm - Earnings Releases ANGIODYNAMICS INC reported fiscal year 2023 results: revenue $342 to $348 million, EPS adjusted earnings per share in the range of $0.01 to $0.06. Guidance reaffirmed. - Period: fiscal year 2023 - Revenue: $342 to $348 million - EPS: adjusted earnings per share in the range of $0.01 to $0.06 - Guidance: reaffirmed - Result: guidance update source text: Management is reaffirming its previously issued fiscal year 2023 guidance. Management expects net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06 as it continues to invest in new product launches to drive future growth. evidence_url: https://www.sec.gov/Archives/edgar/data/1275187/000091412123000003/0000914121-23-000003-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.